Munich\/ Berlin\/ Foster City, Calif. (USA) \u2014 YPOG, with two sepa\u00adrate teams, provi\u00added compre\u00adhen\u00adsive legal advice to the share\u00adhol\u00adders Venrock Health\u00adcare Capi\u00adtal Part\u00adners and Evotec SE on the sale of the biotech company Tubu\u00adlis to Gilead for a total purchase price (inclu\u00adding all earn-out payments) of USD 5 billion. \u2014 The purchase price consists of an imme\u00addia\u00adtely paya\u00adble cash compo\u00adnent of USD 3.15 billion and perfor\u00admance-based payments of up to USD 1.85 billion. The tran\u00adsac\u00adtion is expec\u00adted to close in the second quar\u00adter of 2026. <\/p>\n
Munich-based Tubu\u00adlis<\/strong> is a clini\u00adcal-stage biotech\u00adno\u00adlogy company focu\u00adsed on the deve\u00adlo\u00adp\u00adment of next-gene\u00adra\u00adtion anti\u00adbody-drug conju\u00adga\u00adtes (ADCs). The company\u2019s proprie\u00adtary plat\u00adform tech\u00adno\u00adlo\u00adgies enable the targe\u00adted deli\u00advery of highly potent drugs to tumor cells. Leading deve\u00adlo\u00adp\u00adment programs include TUB-040, an ADC for the treat\u00adment of ovarian cancer and other solid tumors, which is curr\u00adently in clini\u00adcal deve\u00adlo\u00adp\u00adment. In addi\u00adtion, Tubu\u00adlis has a tech\u00adno\u00adlogy plat\u00adform that is geared towards the deve\u00adlo\u00adp\u00adment of new ADC gene\u00adra\u00adti\u00adons and offers broad appli\u00adca\u00adtion poten\u00adtial in oncology. <\/p>\n \u201cThe agree\u00adment to acquire Tubu\u00adlis is a signi\u00adfi\u00adcant mile\u00adstone for Gilead in the field of onco\u00adlogy. The company brings a clini\u00adcal-stage drug candi\u00addate that repres\u00adents a poten\u00adtial new treat\u00adment option for ovarian cancer, as well as a next-gene\u00adra\u00adtion ADC plat\u00adform and a promi\u00adsing early-stage pipe\u00adline,\u201d said Daniel O\u2019Day, Chair\u00adman and Chief Execu\u00adtive Offi\u00adcer of Gilead Sciences.<\/strong><\/p>\n Evotec<\/strong> first inves\u00adted in Tubu\u00adlis in the Series B finan\u00adcing round in May 2022 and then again in the Series B2 finan\u00adcing round in March 2024. Venrock<\/strong> most recently supported the company as lead inves\u00adtor in the Series C finan\u00adcing round.<\/p>\n \u201cThe sale of Tubu\u00adlis marks another important mile\u00adstone for the Euro\u00adpean biotech\u00adno\u00adlogy indus\u00adtry. The tran\u00adsac\u00adtion under\u00adlines the contin\u00adued high inte\u00adrest of stra\u00adte\u00adgic inves\u00adtors in inno\u00adva\u00adtive onco\u00adlogy plat\u00adforms and shows that Euro\u00adpean rese\u00adarch can be successfully trans\u00adla\u00adted into global tran\u00adsac\u00adtions,\u201d says Dr. Martin Scha\u00adper, Part\u00adner at YPOG<\/strong>.<\/p>\n Tubu\u00adlis<\/strong> is deve\u00adlo\u00adping custo\u00admi\u00adzed anti\u00adbody-drug conju\u00adga\u00adtes with outstan\u00adding biophy\u00adsi\u00adcal proper\u00adties that have demons\u00adtra\u00adted sustained tumor deli\u00advery and long-lasting anti\u00adtu\u00admor acti\u00advity in precli\u00adni\u00adcal models as well as in initial clini\u00adcal proof-of-concept studies in plati\u00adnum-resistant ovarian cancer. The two lead programs from the growing pipe\u00adline, TUB-040, targe\u00adting NaPi2b, and TUB-030, targe\u00adting 5T4, are curr\u00adently being evalua\u00adted in the clinic in high-risk solid tumors. Tubu\u00adlis will soli\u00addify its leader\u00adship posi\u00adtion by conti\u00adnuing to drive inno\u00adva\u00adtion in all areas of ADC design utili\u00adzing its proprie\u00adtary plat\u00adform tech\u00adno\u00adlo\u00adgies. \u2014 www.tubulis.com <\/p>\n About Venrock Health\u00adcare Capi\u00adtal Partners About Evotec Advi\u00adsor Venrock Health\u00adcare Capi\u00adtal Part\u00adners: YPOG Team Evotec: YPOG YPOG advi\u00adsed Venrock on this tran\u00adsac\u00adtion toge\u00adther with the US law firm Cooley LLP<\/strong>.<\/p>\n About YPOG <\/p>\n","protected":false},"excerpt":{"rendered":" Munich\/ Berlin\/ Foster City, Calif. (USA) \u2014 YPOG, with two sepa\u00adrate teams, provi\u00added compre\u00adhen\u00adsive legal advice to the share\u00adhol\u00adders Venrock Health\u00adcare Capi\u00adtal Part\u00adners and Evotec SE on the sale of the biotech company Tubu\u00adlis to Gilead for a total purchase price (inclu\u00adding all earn-out payments) of USD 5 billion. \u2014 The purchase price consists of [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":60076,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-60078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\n
\n<\/strong>
\n Venrock Health\u00adcare Capi\u00adtal Part\u00adners (VHCP) is a health\u00adcare-focu\u00adsed venture capi\u00adtal fund group concen\u00adt\u00adra\u00adting on late-stage invest\u00adments. It invests prima\u00adrily in publicly traded small cap and priva\u00adtely held late stage compa\u00adnies \u2014 parti\u00adcu\u00adlarly in the health\u00adcare and life scien\u00adces sectors, with a special focus on biotech\u00adno\u00adlogy. VHCP focu\u00adses on compa\u00adnies that deve\u00adlop and commer\u00adcia\u00adlize inno\u00adva\u00adtive products and tech\u00adno\u00adlo\u00adgies. \u2014 www.venrock.com. <\/p>\n
\n<\/strong>
\n Evotec is a life science company driving the future of drug disco\u00advery and deve\u00adlo\u00adp\u00adment. By combi\u00adning scien\u00adti\u00adfic inno\u00adva\u00adtion with AI-enab\u00adled tech\u00adno\u00adlo\u00adgies and advan\u00adced plat\u00adforms, Evotec acce\u00adle\u00adra\u00adtes the deve\u00adlo\u00adp\u00adment of new thera\u00adpies in a more effi\u00adci\u00adent, precise and scalable way.
\nEvotec\u2019s capa\u00adbi\u00adli\u00adties span small mole\u00adcu\u00adles, biolo\u00adgics, cell thera\u00adpies and rela\u00adted moda\u00adli\u00adties and are supported by proprie\u00adtary plat\u00adforms such as Mole\u00adcu\u00adlar Pati\u00adent Data\u00adba\u00adses, PanO\u00admics and iPSC-based dise\u00adase models. Evotec colla\u00adbo\u00adra\u00adtes with the worl\u00add\u2019s leading phar\u00admaceu\u00adti\u00adcal compa\u00adnies, nume\u00adrous biotech compa\u00adnies, acade\u00admic insti\u00adtu\u00adti\u00adons and other health\u00adcare partners.
\nWith a broad port\u00adfo\u00adlio of proprie\u00adtary rese\u00adarch and deve\u00adlo\u00adp\u00adment projects, Evotec focu\u00adses on key thera\u00adpeu\u00adtic areas such as onco\u00adlogy, cardio\u00advas\u00adcu\u00adlar and meta\u00adbo\u00adlic dise\u00ada\u00adses, neuro\u00adlogy and immu\u00adno\u00adlogy. The Company employs more than 4,800 people world\u00adwide at sites in Europe and the US. \u2014 www.evotec.com <\/p>\n
\n<\/strong>
\n Dr. Benja\u00admin Ullrich (Lead, Tran\u00adsac\u00adtions), Part\u00adner, Berlin
\nDr. Emma Peters (Tran\u00adsac\u00adtions), Asso\u00adcia\u00adted Part\u00adner, Berlin
\nDr. Oliver Junk (Tran\u00adsac\u00adtions), Asso\u00adcia\u00adted Part\u00adner, Cologne<\/p>\n
\n<\/strong>
\n Dr. Martin Scha\u00adper (Co-Lead, Tran\u00adsac\u00adtions), Part\u00adner, Berlin
\nDr. Johan\u00adnes Janning (Co-Lead, Tran\u00adsac\u00adtions), Part\u00adner, Cologne
\nCiro D\u2019Ame\u00adlio (Tran\u00adsac\u00adtions), Senior Asso\u00adciate, Berlin<\/p>\n
\n<\/strong>
\n YPOG stands for You + Part\u00adners of Game\u00adch\u00adan\u00adgers and forward-looking tax and legal advice. The firm advi\u00adses compa\u00adnies focu\u00adsed on future tech\u00adno\u00adlo\u00adgies with the aim of using change as an oppor\u00adtu\u00adnity and jointly crea\u00adting opti\u00admal solu\u00adti\u00adons. The YPOG team offers compre\u00adhen\u00adsive exper\u00adtise in the areas of Funds, Tax, Tran\u00adsac\u00adtions, Corpo\u00adrate, Banking, Regu\u00adla\u00adtory + Finance, IP\/IT\/Data Protec\u00adtion, Liti\u00adga\u00adtion as well as Corpo\u00adrate Crime + Compli\u00adance + Inves\u00adti\u00adga\u00adti\u00adons. YPOG is one of the leading addres\u00adses in Germany for venture capi\u00adtal, private equity, fund struc\u00adtu\u00adring and appli\u00adca\u00adti\u00adons of distri\u00adbu\u00adted ledger tech\u00adno\u00adlogy (DLT) in finan\u00adcial services. The firm and its part\u00adners are regu\u00adlarly reco\u00adgni\u00adzed by renow\u00adned publi\u00adca\u00adti\u00adons such as JUVE, Best Lawy\u00aders, Cham\u00adbers and Part\u00adners, Leaders League and Legal 500. YPOG employs more than 180 expe\u00adri\u00aden\u00adced lawy\u00aders, tax advi\u00adsors and tax specia\u00adlists as well as a notary in its offices in Berlin, Hamburg, Colo\u00adgne, Munich, Cambridge and London. \u2014- www.ypog.law <\/p>\n